1932

Abstract

Nephron-sparing surgery (NSS) provides effective curative therapy for patients with localized renal cell carcinoma. In patients with imperative indications, it represents an alternative to renal replacement therapy. For selected patients with systemic comorbidities that threaten global renal function, NSS preserves unaffected nephrons with excellent cancer-specific survival. Elective partial nephrectomy for patients with a small (≤4 cm), unifocal tumor and a normal contralateral kidney is associated with a low risk (0%–3%) of local recurrence and cancer-specific survival rates of 90%–100%. Comparisons between radical and partial nephrectomy demonstrate equivalent cancer control over five years. Minimally invasive techniques of NSS are feasible but await improved technologies and long-term outcome data before they become fully acceptable treatment options.

Loading

Article metrics loading...

/content/journals/10.1146/annurev.med.53.082901.103937
2002-02-01
2024-06-14
Loading full text...

Full text loading...

/content/journals/10.1146/annurev.med.53.082901.103937
Loading
/content/journals/10.1146/annurev.med.53.082901.103937
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error